ELAN vs. BGNE, SMMT, MRNA, GMAB, VTRS, ITCI, CTLT, RDY, PCVX, and SRPT
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include BeiGene (BGNE), Summit Therapeutics (SMMT), Moderna (MRNA), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.
Elanco Animal Health vs.
Elanco Animal Health (NYSE:ELAN) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
In the previous week, Elanco Animal Health had 4 more articles in the media than BeiGene. MarketBeat recorded 5 mentions for Elanco Animal Health and 1 mentions for BeiGene. BeiGene's average media sentiment score of 0.40 beat Elanco Animal Health's score of 0.00 indicating that BeiGene is being referred to more favorably in the news media.
97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 48.5% of BeiGene shares are held by institutional investors. 0.6% of Elanco Animal Health shares are held by insiders. Comparatively, 7.4% of BeiGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
BeiGene has lower revenue, but higher earnings than Elanco Animal Health. BeiGene is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Elanco Animal Health has a net margin of 4.60% compared to BeiGene's net margin of -25.94%. Elanco Animal Health's return on equity of 6.78% beat BeiGene's return on equity.
Elanco Animal Health has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.
Elanco Animal Health presently has a consensus target price of $16.29, suggesting a potential upside of 35.38%. BeiGene has a consensus target price of $253.69, suggesting a potential upside of 0.00%. Given Elanco Animal Health's higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than BeiGene.
BeiGene received 409 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 68.98% of users gave BeiGene an outperform vote while only 54.33% of users gave Elanco Animal Health an outperform vote.
Summary
Elanco Animal Health beats BeiGene on 10 of the 17 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
This page (NYSE:ELAN) was last updated on 2/1/2025 by MarketBeat.com Staff
